Horizon Pharma ( HZNP ) had its Relative Strength ( RS ) Rating upgraded from 77 to 81 Friday.
[ibd-display-video id=2385970 width=50 float=left autostart=true] This proprietary rating identifies technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the last 52 weeks matches up against that of all other stocks.
Over 100 years of market history reveals that the best stocks tend to have an 80 or higher RS Rating in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
While the stock is not near a proper entry right now, see if it goes on to form and break out of a proper chart pattern.
While earnings growth decreased in the prior quarter from -27% to -63%, revenue grew 30%, up from 12% in the previous report.
The company holds the No. 6 rank among its peers in the Medical-Ethical Drugs industry group. AbbVie ( ABBV ), Zoetis ( ZTS ) and Novo Nordisk ( NVO ) are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
